EPICA International develops, sells, and services advanced medical imaging platforms and robotic systems. They provide solutions for both human and animal imaging.

EPICA International

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earl Bakken

Alfred E. Mann

Daniel Grossman

Palmer Hermundslie

Medtronic plc

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

Stryker Corporation

The Robert Wood Johnson Foundation is a philanthropic organization dedicated to improving health and healthcare in the United States. It focuses on addressing social determinants of health, health equity, and access to quality healthcare.

Metric
Company Name	EPICA International	Medtronic plc	Stryker Corporation	Robert Wood Johnson Foundation
Symbol		MDT	SYK
MSH ID	COM:EPICAINTERNATIONAL	COM:MEDTRONIC	COM:STRYKER	ORG:RWJF
Market	PRIVATE	STOCKS	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare	Healthcare & Health Services
Industry	Medical Devices	Medical - Devices	Medical - Devices	Healthcare and Philanthropy
Country	US	IE	US
Stage	Debt Financing
Employee Count		95K	52K	501
Website	epicainternational.com	medtronic.com	stryker.com	rwjf.org
LinkedIn			stryker
Founders

Metric
Market Cap		98.81B	128.51B
Enterprise Value
Monthly Web Traffic	88	2.66M	1.16M	73.98K
Web Traffic Growth	-0.94	0.29	0.10	-0.26
Valuation
Raised Capital	13.50M

Metric
Revenue	32.36B	20.50B
Revenue (LTM)
Revenue (NTM)
Gross Profit	19.45B	13.06B
EBITDA	8.38B	4.95B
Operating Income	5.73B	3.89B
Net Income	3.68B	3.17B
EPS	2.77	8.34
Diluted EPS	2.76	8.25
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.66	0.64
Operating Profit Margin	0.18	0.20
EBITDA Margin	0.26	0.24
Net Profit Margin	0.13	0.16
Return on Equity	0.08	0.18
Return on Assets	0.05	0.09
Return on Capital Employed	0.07	0.13

EPIC

COM:EPICAINTERNATIONAL

EPICA International

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	28.22	41.17
P/B Ratio	2.25	3.27
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.63	6.62
EV Multiple	12.19	24.94

Metric
Days Sales Outstanding	67.78	67.04
Days Payables Outstanding	71.76
Days Inventory Outstanding	187.43	241.76
Operating Cycle	254.83	304.64
Cash Conversion Cycle	189.62	302.23
Asset Turnover	0.36	0.55

Metric
Operating Cash Flow	6.79B	3.71B
Free Cash Flow	5.20B	3.14B
Cash Flow to Debt	0.27	0.34
Operating Cash Flow/Sales	0.21	0.18
Free Cash Flow Yield	0.03	0.02

Metric
Cash & Equivalents	1.28B	2.97B
Accounts Receivable	-391M	-175M
Inventory	5.22B	4.84B
Goodwill	40.99B	15.24B
Debt to Capitalization	0.37	0.51
Debt to Assets	0.28	0.27
Current Ratio	2.29	1.58
Quick Ratio	1.61	0.99

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01	0.00
R&D to Revenue	0.08	0.07
SG&A to Revenue